Currently, staging, endocrine receptor and HER-2 status, and Ki-67 and tumor grade define adjuvant treatment choices, occasionally supported by genetic signature tools such as OncotypeDx and Prossigna. The gene discussed is ERBB2; the disease is neoplasm.